The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.90BHKD
497.01M · vs all stocks (USD)
Updated Oct 24, 2026
Trailing P/E
146.67x
vs Diagnostics & Research peers
Updated Oct 24, 2026
Revenue (TTM)
3.11BCNY
396.93M · vs all stocks (USD)
Updated Oct 24, 2026
Profit Margin
0.87%
vs Diagnostics & Research peers
Updated Oct 24, 2026
Beta
0.0870x
vs all stocks
Updated Oct 24, 2026
52-Week Change
-27.69%
vs all stocks
Updated Oct 24, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Market Capitalization
3.90BHKD
497.01M · vs all stocks (USD)
Updated Oct 24, 2026
Enterprise Value
4.80BHKD
611.93M · vs all stocks (USD)
Updated Oct 24, 2026
Trailing P/E
146.67x
vs Diagnostics & Research peers
Updated Oct 24, 2026
Forward P/E
23.40x
vs Diagnostics & Research peers
Updated Oct 24, 2026
Price to Sales (TTM)
1.19x
vs Diagnostics & Research peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 1.25×.Updated Oct 24, 2026
Price to Book (MRQ)
1.53x
vs Diagnostics & Research peers
Updated Oct 24, 2026
Enterprise to Revenue
1.54x
vs Diagnostics & Research peers
Updated Oct 24, 2026
Enterprise to EBITDA
14.73x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 14.17×.Updated Oct 24, 2026
Profit Margin
0.87%
vs Diagnostics & Research peers
Updated Oct 24, 2026
Operating Margin
5.70%
vs Diagnostics & Research peers
Updated Oct 24, 2026
Return on Assets (TTM)
2.10%
vs Diagnostics & Research peers
Updated Oct 24, 2026
Return on Equity (TTM)
1.62%
vs Diagnostics & Research peers
Updated Oct 24, 2026
Revenue (TTM)
3.11BCNY
396.93M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue per Share (TTM)
3.69CNYUpdated Oct 24, 2026
Quarterly Revenue Growth
1.10%
vs Diagnostics & Research peers
Updated Oct 24, 2026
Gross Profit (TTM)
1.16BCNY
147.44M · vs all stocks (USD)
Updated Oct 24, 2026
EBITDA (TTM)
338.77MCNY
43.18M · vs all stocks (USD)
Updated Oct 24, 2026
Net Income (TTM)
27.21MCNY
3.47M · vs all stocks (USD)
Updated Oct 24, 2026
Quarterly Earnings Growth (YoY)
17.40%
vs Diagnostics & Research peers
Updated Oct 24, 2026
Operating Cash Flow (TTM)
291.16MCNY
37.11M · vs all stocks (USD)
Updated Oct 24, 2026
Levered Free Cash Flow (TTM)
279.20MCNY
35.58M · vs all stocks (USD)
Updated Oct 24, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Trailing Annual Dividend Rate
0.00HKDUpdated Oct 24, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Oct 24, 2026
Minority Interest (Equity)
128.67MCNYFY2025 · Dec 31, 2025
Revenue
2.64BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
1.69BCNYFY2025 · Dec 31, 2025
Gross Profit
952.48MCNYFY2025 · Dec 31, 2025
Operating Income
157.31MCNY
23.60M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
51.78MCNYFY2025 · Dec 31, 2025
Income Tax Expense
29.04MCNYFY2025 · Dec 31, 2025
Net Income
22.75MCNYFY2025 · Dec 31, 2025
EBIT
100.29MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
338.77MCNYFY2025 · Dec 31, 2025
Research & Development
103.67MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
701.34MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
13.19MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
48.51MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.0300CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.0300CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
714.50MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
714.50MSharesFY2025 · Dec 31, 2025
Minority Interests (P&L)
-4.30MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
129.31MCNYFY2025 · Dec 31, 2025
Free Cash Flow
29.63MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
1.10BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
51.78MCNYFY2025 · Dec 31, 2025
Stock-based Compensation
4.94MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
35.32MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
37.46MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-194.00KCNYFY2025 · Dec 31, 2025
Capital Expenditures
-99.69MCNYFY2025 · Dec 31, 2025
Net Intangibles (CF)
-3.35MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-34.89MCNYFY2025 · Dec 31, 2025
Sale of Investments
0.00CNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-134.57MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
605.88MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-491.62MCNYFY2025 · Dec 31, 2025
Common Stock Repurchase
-46.57MCNYFY2025 · Dec 31, 2025
Other Financing Charges
13.57MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
81.26MCNYFY2025 · Dec 31, 2025
Shares Outstanding
717.84MSharesUpdated Oct 24, 2026
Float Shares
234.11MSharesUpdated Oct 24, 2026
% Held by Insiders
22.47%
vs all stocks
Updated Oct 24, 2026
% Held by Institutions
43.96%
vs all stocks
Updated Oct 24, 2026
Total Cash (MRQ)
1.03BCNY
131.07M · vs all stocks (USD)
Updated Oct 24, 2026
Total Cash per Share (MRQ)
1.22CNYUpdated Oct 24, 2026
Total Debt (MRQ)
1.90BCNY
241.69M · vs all stocks (USD)
Updated Oct 24, 2026
Total Debt to Equity (MRQ)
0.8624x
vs Diagnostics & Research peers
Updated Oct 24, 2026
Current Ratio (MRQ)
1.52x
vs Diagnostics & Research peers
Updated Oct 24, 2026
Book Value per Share (MRQ)
2.87CNYUpdated Oct 24, 2026
Total Assets
4.80BCNY
720.54M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
3.01BCNYFY2025 · Dec 31, 2025
Total Liabilities
2.95BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
1.79BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
857.35MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
2.10BCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
170.97MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
4.55MCNYFY2025 · Dec 31, 2025
Accounts Receivable
1.70BCNYFY2025 · Dec 31, 2025
Inventory
129.28MCNYFY2025 · Dec 31, 2025
Accounts Payable
696.97MCNYFY2025 · Dec 31, 2025
Short-term Debt
822.79MCNYFY2025 · Dec 31, 2025
Long-term Debt
828.03MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
4.00MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
97.00KCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.85BCNY
277.39M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
61.08MCNYFY2025 · Dec 31, 2025
52-Week Low
3.16HKDUpdated Oct 24, 2026
52-Week High
7.63HKDUpdated Oct 24, 2026
52-Week Change
-27.69%
vs all stocks
Updated Oct 24, 2026
Beta
0.0870x
vs all stocks
Updated Oct 24, 2026
50-Day MA
4.06HKDUpdated Oct 24, 2026
200-Day MA
4.21HKDUpdated Oct 24, 2026
Avg 10-Day Volume
69.65KSharesUpdated Oct 24, 2026
Avg 30-Day Volume
105.32KSharesUpdated Oct 24, 2026
Diluted EPS (TTM)
0.0300CNYUpdated Oct 24, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Well below its peak, with three years of positive free cash flow behind it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 146.67×, higher than 95% of its Diagnostics & Research peers (median 47.79×)Significant